The clinical introduction of the pTau217 blood test in the EU and Switzerland marks a significant advancement in Alzheimer’s diagnosis. This innovative test identifies Alzheimer-related deposits with over 90% accuracy, without the need for invasive procedures. It offers a cost-effective alternative to traditional PET scans and lumbar punctures, making early detection more accessible.
Approvals and Key Players
Multiple medical technology companies have launched respective testing procedures. A key manufacturer received CE marking for its assay under the European IVDR regulation on July 7, 2026. The first pTau217 blood tests were approved across the EU as of May, and they have been gaining traction in clinical settings since early July.
Leading providers in this field include Roche, Fujirebio, and Beckman Coulter, who supply automated systems enabling widespread laboratory use. The cost per examination ranges from €100 to €150, making it a feasible option for many medical facilities.
It is critical to note that the blood test is not intended for mass screening. Instead, it should be integrated into a comprehensive diagnostic process, based on justified suspicion. At present, statutory health insurance in Germany does not cover the costs for these tests.
Current Research Data
The new pTau217 blood test distinguishes Alzheimer deposits with remarkable accuracy, thus eliminating the discomfort associated with lumbar punctures. It is essential for identifying suitable participants for preclinical Alzheimer studies and showcases its efficacy at the Alzheimer’s Association International Conference (AAIC) held in London in mid-July.
Pharmaceutical firms presented new data, with one Swiss company revealing insights from its portfolio—including results from phase-3 studies of a new antibody. Industry representatives demonstrated how their testing methods compare favorably to Amyloid-PET scans, particularly highlighting the reliability of blood tests for individuals without cognitive impairments.
Complementary long-term data concerning approved therapies such as Donanemab and Lecanemab, which received EU approval in 2025, were also discussed, illustrating the evolving narrative surrounding Alzheimer’s treatment and diagnosis.
Prevention and Complementary Strategies
Alongside these blood tests, lifestyle-based preventive strategies are gaining prominence in combatting dementia. Medical reports suggest that up to 45% of dementia cases could potentially be prevented through lifestyle modifications.
Adopting simple lifestyle adjustments can significantly reduce individual risk. For instance, daily walks of just 3,000 steps can slow the accumulation of tau proteins and may postpone the onset of Alzheimer’s by about three years. Furthermore, the MIND diet can lower dementia risks by up to 35%. Pharmacological data suggests that SGLT2 inhibitors can reduce Alzheimer’s risk by 43%, while GLP-1 receptor agonists may lower it by 33%.
As an additional measure, the LMU Hospital in Munich has implemented an open PET scanner to enhance patient comfort during examinations. Pilot projects began in Bavarian pharmacies in early July, offering memory checks for individuals over 60. Concurrently, Austria introduced a digital chatbot, PIA, designed to assist patients and their families in navigating the diagnostic system.
Disclaimer: This article does not constitute investment advice or buy/sell recommendations. Data regarding prices, companies, and markets are without guarantee and subject to change. Trading in financial markets can lead to significant losses. Our contributions are partly automated and reviewed with the assistance of AI.
